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ABSTRACT 
Thirty three subjects diagnosed with Chronic Fatigue 
Syndrome and 37 healthy matched controls were paired and 
given either selenium or neutral supplementation to take 
for six weeks. Blood testing before and after completion 
of the trials confirmed changes in selenium blood levels. 
All subjects completed the Profile Of Mood States (POMS) 
and Beck Depression Inventory (BDI) Questionnaires on 
three occasions. Mood scores and BDI scores were analyzed 
and results indicate a marked increase in mood for CFS 
subjects on selenium compared to CFS subjects on placebo. 
There was no significant mood change for controls on 
either treatment. Analysis of the 6 POMS sub-scores also 
revealed that CFS mood profile was different from the mood 
profile of healthy controls. 
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Chapter 1 INTRODUCTION 
The purpose of this study was to examine the effect of 
selenium supplementation on the general mood states of 
both Chronic Fatigue Syndrome (CFS) subjects (a condition 
also known as Myalgic encephalomyelitis or ME) and healthy 
Non-CFS subjects acting as controls. Before we examine 
the current understanding on the condition of CFS, some 
explanation of the controversy over the use of the term ME 
needs to be made. This will help to put into perspective 
the often strange difficulties that some of the research 
findings have generated both for those in the medical 
profession and those who have been diagnosed as having 
CFS. 
1.01 Historical Perspective 
Historically, the term ME was first used by Dr Ramsay in 
1956, following the appearance of the Royal Free Disease 
epidemic in London (Ramsay 1988). His medical report 
described the symptoms of ME as characterized by nervous 
abnormalities (facial paralysis, difficulty in swallowing, 
severe muscle pain and loss of skin sensitivity 
(hypaesthesia). Unfortunately, scientific attempts at the 
time to discover the cause or causes did not have any 
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success. Similar epidemics with basically the same 
symptoms were known to have occurred as early as 1934 (in 
the USA) and were variously named Endemic Neuromyasthenia, 
Royal Free Disease, Post Infectious Neuromyasthenia, 
Chronic Mononucleosis, Chronic Epstein Barr Virus disease 
(CEBV), Post Viral Fatigue syndrome and Chronic Fatigue 
Syndrome ( even "Yuppie Flu") • It is important to note 
that the major characteristic features of these syndromes 
were muscle fatigue, pain and experiences of tiredness on 
exertion and depressive thought patterns related to 
psychological disturbances (Murdoch 1988, Behan 1981). 
1.02 ME or CFS - A CONTROVERSY 
In 1985, at Lake Tahoe (Nevada), an epidemic of similar 
nature brought more urgent attention to the issue of CFS 
recognition. But again the follow up checks made at Lake 
Tahoe to identify possible causes were not successful. 
The media reported these epidemics as flu-like temporary 
infections that were soon to pass. However, a more 
careful examination of patients immune system soon 
revealed a higher than normal level of antibodies (Murdoch 
1988), implying an exposure to some sort of pathogen. 
This finding intensified the search for signs of Epstein 
Barr Virus (EBV), a virus commonly associated with 
glandular fever. Again, no conclusive result was reached, 
but the investigation did reveal apparent defects in the 
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immune system (Fark 1990). In the media, such outbreaks 
were labelled as Chronic Epstein Barr Virus (CEBV) 
epidemics. Yet the symptoms of CEBV were considered to be 
the same as for Chronic Fatigue Syndrome (CFS) because 
both referred to the same characteristic group of symptoms 
(syndrome) . However, those in the forefront of this 
research were somewhat hesitant to confirm or even 
acknowledge that the etiology of chronic fatigue somehow 
derives from the presence of EBV in body tissue. However, 
the symptoms of "Chronic Fatigue" can be traced to muscle 
pathology but the term "Myalgic encephalomyelitis" 
suggests a nervous and muscular disorder which has not yet 
been verified by pathologists. Nor has there been any 
useful diagnosis of psychological or psychiatric disorder 
that includes the major symptoms· of the CFS syndrome. 
Because of this uncertainty, the term CFS became more 
acceptable to scientists (Holmes, et al 1988) since it 
clearly describes an identifiable feature of the syndrome, 
rather than suggesting a possible cause that is not yet 
known. Hence the empirical nature of the CFS label was 
attracting a more positive response from the scientific 
community than the ME label. But basically, the medical 
profession are referring to the same set of symptoms or 
syndrome no matter which term is used. Abbey and 
Garfinkel (1990) have pointed out that the Americans and 
Canadians have only recently accepted the CFS term but the 
world wide support groups still prefer Myalgic 
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encephalomyelitis (ME) because CFS is considered to be a 
trivialisation of the ME condition. 
The medical profession is therefore not always in uniform 
agreement or support of the various diagnoses available 
for a number of reasons. The most important is the lack 
of empirical medical data to provide a basis for the 
diagnosis. As a result, many practitioners would not have 
anything to do with attempts to diagnose the CFS syndrome. 
In the Otago region, most medical practitioners would 
refer patients on to the School of General Practice (Otago 
Medical School) for Professor Murdoch to assess diagnosis 
of a CFS syndrome. But in a recent article (Otago Daily 
Times 6 May 1992), Murdoch was quoted as saying that his 
efforts to develop a definitive and acceptable diagnosis 
for the syndrome has not always been well received by the 
medical profession. Not all members of the profession can 
totally agree with the emphasis placed on the environment 
as an important factor in the development of the CFS 
condition. Murdoch seems to believe that the present 
medical crisis of increasing human vulnerability to viral 
and immunological dysfunctions (e.g AIDS) is partly due to 
a deteriorating world wide environment. 
As already pointed out, the controversy associated with 
the study of CFS is linked to the presence of many 
versions and labels for the condition, each with its own 
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variation in emphasis. In this thesis, I shall remain 
impartial to the controversy and from here on, the label 
CFS shall be used to refer to the same syndrome referred 
to as ME - but the latter term will be used where it has 
been accepted in those reports being discussed in the 
current thesis. 
All CFS subjects chosen for this study were either 
diagnosed by Professor Murdoch (Department of General 
Practice, Otago Medical School) or other medical 
practitioners who later refers the case to Murdoch for 
confirmation. Unfortunately the diagnosis of CFS is not 
always a clear-cut matter but there does appear to be a 
growing confidence amongst some GP's that despite the lack 
of empirical data, the often debilitating nature of the 
condition does require a more sympathetic approach. 
Besides that, there is also a growing acceptance by the 
media and the public ( as a result of efforts by the 
various support groups like the ME Society) that the CFS 
condition is real - even if it was still without 
conclusive evidence that might convince the scientific 
community but in particular the medical profession. 
1.03 THE RECURRENT FEATURES OF CFS 
ME, according to Murdoch's ( 1987) clinical survey, is 
characterized by a number of recurring features. These 
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are mainly symptoms of irritability, emotional stress, 
palpitation and abdominal difficulties. ME subjects have 
also been identified on the basis that the syndrome they 
presented involved: 
1. a short history of illness lasting more than three 
months. 
2. a recurrent pattern of illness relapses. 
3. a recurrent pattern of exhaustion, muscle pain and 
weakness during exercise. 
A similar pattern of symptoms have been generally accepted 
and used for diagnostic purposes elsewhere (Prasher et al 
1990). The symptoms are not difficult to recognise and 
some practitioners who make the attempt to diagnose seem 
to have little difficulty recognising the condition. The 
problem is to distinguish these symptoms from those of 
many other conditions • Hence, there are many 
uncertainties about the basic nature of the condition. 
Some believe it is psychiatric in nature (McEvedy & Beard 
1973). Some consider it to be a physiological problem 
relating to current infections or immune dysfunctions -
i.e a medical problem (Lynch et al 1989). These 
uncertainties have lead scientists to a number of 
investigations that has generated various reports and 
debates. The most significant of these debates is 
centred around the cause of the CFS condition. In the 
following section we will examine this very debate and 
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consider not only the attention given by the medical 
profession but also that by the public and support groups 
of CFS/ME sufferers. 
1.04 MEDICAL OR PSYCHOLOGICAL PROBLEM? 
The literature by both CFS sufferers (Horne 1991) and 
health professionals (McIntyre 1989, Shepherd 1989) 
reflects a common concern at the lack of supportive data 
for establishing ME as a bonafide medical condition. Some 
have suggested "its all in the mind" (McEvedy, et al 1978) 
or that sufferers were mentally disturbed (Kroenke 1991). 
Those who withdraw from the work force, as a consequence 
of their illness, are sometimes accused of malingering. 
In her Thesis, Sylvia Horne (1990) describes the traumatic 
daily experiences of the ME sufferer as the "daily battle 
with despair." The despair is generated from the 
experience of disbelief and shock that CFS sufferers 
discover when they try unsuccessfully to share their 
problems with unsympathetic health authorities or 
colleagues (and sometimes unhelpful family members). The 
general lack of professional recognition of this illness 
adds more pressure on those already diagnosed by some 
practitioners as having the syndrome. Psychiatrists 
(McEvedy et al 1973) have suggested a diagnosis of 
psychological dysfunction in some instances of CFS 
epidemics. But this diagnosis is based on conceptual 
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rationalisations developed from the belief that sufferers 
have unresolved inner conflicts and emotional stresses. 
Unfortunately this approach so far seems far less 
convincing than the condition itself. 
Most CFS sufferers and medical practitioners do not share 
this view which is accepted by some Psychiatrists. 
However efforts to evaluate significant psychological 
elements in CFS are being pursued in order to understand 
the psychological parameters of the condition. Recently 
some important findings with mood studies and depression 
in patients diagnosed as having CFS have been reported. 
1.05 MOOD DISORDERS AND COGNITIVE DEFICITS IN CFS SUBJECTS 
The incidence of mood disorders amongst CFS subjects is 
always a matter of great concern and one that needs 
careful attention. 
Surprisingly, relatively little has actually been done to 
determine the psychological correlates of the CFS 
condition. However, as the following report shows, 
psychiatric and psychological disorders have been 
identified in some CFS sufferers. 
A retrospective 
indicated the 
analysis of CFS patient history has 
possibility of psychiatric disorders 
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preceding the onset of the chronic fatigue syndrome. 
Kruesi et al (1989) used the National Institute of Mental 
Health Diagnostic Interview Schedule (NIMH/DIS) to study 
the lifetime prevalence of psychiatric disorders in 2 8 
patients classified as having CFS. The results from these 
subjects were compared to those obtained from chronically 
and medically ill patients and from healthy individuals. 
The comparison revealed that the rate of psychiatric 
illness (phobia,somatization,depressive and panic 
disorders) amongst CFS subjects was higher than for the 
healthy and medically ill(non-psychiatric) group. Kruesi 
concludes that psychiatric disorders amongst CFS subjects 
seem to occur more often before rather than after they 
were diagnosed with CFS. 
that the CFS syndrome 
In particular, it would appear 
may be linked to psychiatric 
disorders like depression. 
In their examination of 100 CFS patients, Manu et al 
(1989), found a consistent prevalence of depressive mood 
disorders in the group as a whole. This finding was also 
based on patients' medical history and evaluation of 
psychological profiles from the NIMH/DIS and Beck 
Depression Inventory (BDI) scores. The study examined 
each patient's history, physical and laboratory findings. 
From this examination, it was found that twenty-three of 
forty-four CFS subjects with depressive illness had 
experienced their first depressive episode before they 
15 
were diagnosed as having CFS. The overall findings 
however were only modest in distinguishing the severity of 
CFS group from the Non-CFS group that also experienced 
depression. Again, Manu concludes that not only were the 
signs of depressive illness an important precursor to the 
CFS syndrome. One outcome of this research is the 
suggestion that there may be a psychological component 
that predates the onset of CFS. This suggestion was 
carefully examined in the important studies that follow. 
Taerk (1987) who examined the prevalence of a depressive 
disorder and symptoms in 24 subjects with neuromyasthenia 
(using the BDI) also found 67% had major depression. 
Hickie et al (1990), found signs of depression in 45 of 48 
CFS subjects, but their findings suggested that depression 
arose as a consequence of developing CFS rather than 
precipitating the occurrence of CFS. Of the 45 CFS 
patients that Hickie et al studied, 24 were diagnosed with 
non-endogenous depression and this was sometimes 
associated with mild forms of panic disorders. There were 
no cases of generalised anxiety disorders although a few 
reported simple phobias and one serious case of 
somatisation disorder (Briquet's disorder). According to 
Hickie, the pattern of current symptom and history of 
psychiatric disturbances in CFS patients is not the same 
as that shown by NON-CFS psychiatric patients. CFS 
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patients did not have the high pre- morbid rate of 
psychiatric disorders seen in other psychiatric patients. 
They were also less neurotic and at their worst, did not 
display the psychometric profile of non-endogenous 
depressive comparison group studied by these workers. 
Also there seemed to be no evidence that the CFS condition 
is some form of somatic representation of an underlying 
psychological condition. Hickie' s use of the Eysenck 
Personality Inventory (EPI) and general health 
questionnaire also significantly concluded that CFS 
subjects were less neurotic in behaviour than psychiatric 
patients with neurotic conditions. 
Frasher, et al (1990) reported that CFS patients may have 
deficits in the areas of cognitive and sensory perception. 
In this investigation, the assumption was made that CFS 
subjects may experience some form of sensory and cognitive 
disturbance which could be associated with neural 
deficits. To examine this assumption synchronous neural 
activity involving specific stimulus material was measured 
using two types of evoked potentials, sensory potentials 
for brain-stem, visual and somatosensory changes . 
Firstly, sensory evoked potential readings were made in 
three separate areas. 
that were generated 
stimulation at 10 Hz 
Readings from Brainstem potentials 
by alternating polarity click 
with electrodes placed on the 
forehead. Visual potentials were recorded from visual 
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observations of a checkerboard pattern reversal stimulus 
generated by the Mistral system. Somatosensory potentials 
were also recorded from median nerve stimulation by 
cervical spine (Cv2) electrode stimulation. 
Secondly, cognitive evoked potentials were elicited by two 
auditory discrimination tasks that involved subjects 
responding to either frequency or varying duration of 
tone. Subjects' task was to react to a target tone by 
pressing a response button as quickly as possible. The 
time taken to react were recorded as measures of 
responses. 
This examination of multi-modality sensory-evoked 
potentials in CFS subjects found attention deficits and 
slower speed of information processing in CFS subjects. 
In the area of endogenous event-related potentials, 
cognitive potentials related to frequency and duration 
responses appear to be absent or significantly delayed in 
52% of CFS patients. This would appear to support the 
widely acknowledged CFS complaint of cognitive impairment 
in the areas of memory disturbances and lack of ability to 
concentrate. However, the main concern by Prasher et al 
was to identify any differences in evoked potentials in 
both CFS and non-CFS subjects. Clearly in the area of 
sensory potentials of the visual, auditory brainstem and 
median nerve somatosensory systems, CFS subjects seemed 
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unaffected. This finding would therefore support the view 
that CFS subjects do not appear to suffer any biological 
disorder of the Central Nervous System. This distinction 
is important in that it is somewhat in contrast to 
abnormal sensory evoked potentials in subjects with 
multiple sclerosis - subjects who often display symptoms 
of CFS during the early phase of the development of 
multiple sclerosis. 
Recently, Smith (1992) summarized two British studies (in 
press) that investigated memory ,attention and motor 
function in CFS subjects using a questionnaire/ survey 
method and objective testing to assess emotional behaviour 
aspects and performance characteristics of CFS and control 
subjects. The findings indicate CFS subjects expressed 
concentration problems, memory impairments, higher levels 
of anxiety, somatic problems and depressions. They also 
found evidence of slower motor performance , memory 
deficits, increased visual sensitivity on various 
objective tests including impaired reaction times, poorer 
word recognition and free re-call primacy as well as 
impaired logical reasoning. However their evidence 
suggested that these impairments were unlikely to reflect 
global intellectual functioning impairments or that the 
performance impairment might be the result of depression. 
There may be little doubt that people who suffer prolonged 
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bouts of neuromuscular pain, constant alimentary 
dysfunctions and experience recurring memory lapses that 
in the end may succumb to some form of psychological 
illness and at worse, perhaps develop a psychiatric 
condition relating to stress. 
Many other workers emphasise the possibility of a somatic 
basis involving pathogens and the immune system rather 
than a psychiatric or neurological dysfunction. Hence the 
role of virus and the immune system is an important aspect 
of the study of the CFS syndrome. 
1.06 VIRUSES AND THE IMMUNE SYSTEM 
In the USA, persistent efforts by medical practitioners 
dealing with CFS led researchers to re-examine the 
question of viral infections identified in earlier studies 
of CFS patients. It is perhaps worth noting that the 
technical and scientific developments in the discipline of 
virology and immunology have been partly responsible for 
the increasing acceptability of CFS as a condition worthy 
of medical attention. At best, the study of viruses and 
how they can be controlled is difficult enough. But 
attempts to link its presence with CFS has been a more 
difficult task. Never the less there have been some 
important breakthroughs reported by Murdoch and Behan 
including a recent success in the USA with virus 
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implicated in CFS studies. 
One of the suspected viral elements is a retrovirus, a 
relative of the kind that causes AIDS. These retroviruses 
contain the enzyme reverse transcriptase that converts 
viral RNA into cytoplasmic DNA either from 
extrachromosomal sites or from within the host cell 
nucleus where it coordinates activities within the cell 
DNA. Unfortunately, all three categories of retrovirus 
seem to have a natural affinity for attacking T4 
lymphocytes (inducer/helper cells) and this will 
invariably lead to an imbalance in the ratio of T4: Ts 
suppressor cells, thus creating difficulties within the 
immune system. These difficulties arise because the Ts 
suppressor will act to suppress the immune system in the 
absence of sufficient regulatory T-Helpers that co-
ordinate production of more anti-bodies. The two groups 
of viruses of major concern in current CFS research are 
the cytomegalovirus and the enterovirus. 
1.06.A PERSISTENT (LATENT) CYTOMEGALOVIRUS 
The most frequently occurring latent virus identified in 
CFS patients is the Epstein-Barr virus. A persistently 
high EB virus capsid IgG titre value (which indicates 
presence of the EB virus) was found in a CFS patient, who 
had ten years earlier suffered illness following an 
21 
initial chronic condition of viral infection ( Shepherd 
1989). However, to complicate matters, it is also known 
that EBV capsid IgG titre values may be the product of 
constant reinfections due to latent EB virus in the throat 
tissues (Shepherd 1989). The problem here may be twofold. 
Firstly, the possibility of a persistent viral infection 
that induces illness, or secondly, the partial destruction 
of the body's immune system such that the individual is 
unable to deal with the body's daily contact with 
pathogens. 
The pathology of Epstein-Barr virus and its effect on the 
immune system of carriers were closely re-examined for a 
possible cause of the ME condition. Holmes (personal 
communication) , has indicated that there is sufficient 
evidence to seriously suspect immune dysfunction as a 
prime cause of the CFS condition. At present there is 
also a sense of optimism amongst New Zealand researchers 
that the underlying cause could be viral in nature: 
Somehow, during the development of viral infection, the 
body's immune system has become dysfunctional and no 
longer copes with the body's daily exposure to pathogens 
and stress. An example is the reduction in regulatory T 
lymphocytes within the immune system. This reduction can 
affect the level of T suppressor (which reduces the 
production of lymphokines) as well as levels of T Helper 
Cells. The lowering of lymphokines reduces the level of 
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stress related to the symptoms of malaise, muscle pain and 
general discomfort following the immune systems response 
to pathogens. Shepherd ( 1989), has reported studies of 
subjects who were treated with interferon and others who 
were producing excessive interferon. In these studies, 
both groups produced more lymphokines and gradually 
developed some of the major symptoms of CFS, i.e. muscle 
fatigue and soreness. 
1.06.B ENTERO VIRUS 
The other group of virus that is suspected in the 
development of the CFS syndrome are pathogens that are 
harboured inside the alimentary system called enterovirus. 
The enteroviruses that live inside the gut system, but in 
particular the Coxsackie type, have been identified as 
present in the tissue of many CFS sufferers (Bell, et al 
1988). The entero virus includes some deadly varieties 
that can attack the nervous system. The best known of 
these are the polio virus and the echoviruses that are 
responsible for the paralytic and often fatal diseases 
like meningitis (meningoencephalitis) [Merck Manual 1987]. 
To this day there are still no known cures for these viral 
infections. Fortunately, scientists have now developed 
specific tests that can identify parts of both the 
Coxsackie B and Epstein-Barr Virus (Holmes, 1991). 
Further more, studies of antibodies and lymphocyte 
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functions in patients with the Coxsackie B Virus have 
revealed deficits in both lymphocytes and the number of 
suppressor cells in the system of acutely ill CFS 
patients. 
As previously discussed, immune deficits mean that people 
with CFS do not have adequate defence systems to combat 
microbial invasions of body tissue. The effort to ward 
off infection by the body's immune system is an on-going 
biological process involving a number of factors: The 
humoral immunity system producing immunoglobulin and the 
cellular immunity system producing specific lymphocytes 
like the B and T-lymphocytes. If these fail to 
materialize in the appropriate manner in response to 
foreign particles, the body system is likely to encounter 
biochemical stress as toxins from viral and bacterial 
cells develop within the body. 
1.07 VIRUS AND CFS 
Much of what is currently known about the role of viruses 
in CFS is still speculative. There is currently no hard 
evidence that viruses are causing muscle fatigue in CFS 
patients. Nor is it clear if they are responsible in any 
way for the triggering of pain or fatigue experienced by 
CFS sufferers. Never the less their presence in the body 
is today taken seriously enough for virologists to 
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continue investigations into their (viral) activities and 
possible physiological implications. 
One recent speculation is that viral replication within 
host tissue may create physiological changes that are 
destructive of host organ and tissue development (Shepherd 
1989). Viral units cannot reproduce on their own but are 
able to do so inside the host cell using the cells DNA 
mechanism. It is also now suspected that mutations by 
viral filaments within the host could also lead to basic 
changes within the autoimmune system. It is thought that 
this kind of change may arise directly from viral growth 
or from the bodies autoimmune mechanism reacting against 
the presence of virus. A number of modifications could 
happen as seen for example in the way retrovirus like the 
flu virus (found latent in CFS patients) will spread new 
infections after being dormant for months or even years 
(Holmes, 1991). One mechanism by which this event occurs 
lies in the ability of these microbes to infiltrate the 
genetic centre of the cell and effectively replicate 
together with the host cell when the latter is in the 
process of making new cells. This replication however, 
becomes more insidious when the cells being regenerated 
are the body's white cells, activated in response to the 
presence of pathogens in the body. In other words the 
spread of infection is accelerated when the body's immune 
system attempts to respond to the presence of a virus. 
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Not all investigators ( Simpson 1991, Mukherjee et al, 
1987, Lloyd et al, 1989) however, would agree that viruses 
alone could be responsible for all of the CFS condition. 
1.08 VASCULAR INSUFFICIENCY 
At the Prince of Wales - Prince Harry Hospital in 
Australia, there was speculation that gross abnormality in 
red blood cells made blood flow very difficult in the 
capillaries - thus creating a fatigue-like condition as 
seen in the case of long distance runners. This 
observation by Mukherjee (1985) was further developed by 
Simpson (1990) at Otago Medical School, who suggested that 
a discoid shape red cell problem was also a possible cause 
of muscle fatigue both in CFS sufferers and in other 
conditions like hepatitis. The hepatitis condition, 
according to Simpson,is characterised by the early 
appearance of a flu like illness that later develops into 
symptoms of physical and mental exhaustion in CFS 
patients. A check on patients, during the early stages of 
hepatitis, evidently reveals an increased number of non-
discocytic erythrocytes in the blood (Simpson 1990). 
However, it is not known for sure if the fatigue 
experienced by ME sufferers relates to the shape or 
function of red cells in the blood Simpson, 
nevertheless, is pursuing this matter in research in the 
hope of establishing a relationship between the experience 
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of fatigue and impairment of blood flow through body 
organs. Other scientists in New Zealand and USA suspect 
more obvious causes like the presence of parasites. 
1.09 THE ROLE OF PARASITIC SPIROCHAETE 
In 1975, an outbreak of an arthritic-like disease in 
children occurred in a small town of Lyme (Connecticut) in 
the USA. Examination of the problem revealed the cause to 
be the spirochaete Borrelia burgdorferi a disease 
transmitted by ticks like Ixodes dammini found commonly on 
the coat of domestic pets. It is evidently possible for 
spirochaete' passed on by pets (cat, dog) to remain 
dormant in human body tissue and create an illness 
condition during its parasitic existence. 
The spirochaete has been found in blood, spinal fluid, 
skin lesions (erythema chronicummigrans),inflamed synovia 
and other organs of the body. The symptoms are quite 
unusual. There is an onset of arthritic soreness in the 
joints which is associated with obliterative endarteritis 
and erosion of cartilage and sometimes bone. Then there 
is the characteristic development of the immune response 
system which is evident by the very high level of serum 
IgM in the blood. Further more, there is development of 
the more common symptoms of malaise, fatigue, fever and 
headaches with fatigue and malaise lasting several weeks 
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after the other symptoms have retracted. 
In the USA, Lyme disease is the most commonly reported 
tickborne illness to affect both sexes and virtually all 
age groups - although there is a tendency to affect 
younger adults and children. 
Snow (Otago Daily Times 1989) reported in a news article 
that the work being done in the USA to identify and deal 
with these microbes may reveal some causal mechanism for 
the development of ME. As he points out, spirochaete 
have a habit of infiltrating deeply into the host muscle 
tissue and remaining undetected for years but often only 
causing intermittent illnesses without showing up in blood 
or smear tests. It seems reasonable to suspect that the 
toxins released from these parasites will contribute to 
the feeling of sickness experienced by the host and could 
perhaps explain the muscle fatigue and feeling of weakness 
typical of ME symptoms. There might be a link between the 
incidence of CFS epidemics and prevalence of pet keepers 
in particular areas, but at the moment in New Zealand, 
this matter has not been considered very seriously. 
1. 10 CAN MINERAL DEFICITS MAKE SOME PEOPLE MORE 
SUSCEPTIBLE TO THE CFS SYNDROME? 
One issue that is being taken more seriously in New 
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Zealand with respect to CFS is the matter of mineral 
deficits. 
Many CFS patients who are fortunate enough to be treated 
by their GP are usually put on a combination of mineral 
and vitamin supplements for several months if not years. 
This raises a number of important questions. Are there 
any health conditions affected by mineral deficits in New 
Zealand? Is CFS in any way caused by mineral deficits? 
Is there evidence that supplementation improves the well-
being of CFS sufferers and how useful this type of therapy 
is in dealing with the CFS syndrome. 
In New Zealand, as in Britain and parts of the USA, China 
and the Nordic countries, the very low level of certain 
minerals in the natural food source may lead to the 
speculation that some people may become susceptible to 
viral infections as a result of natural mineral deficits. 
It is known that certain mineral deficits can lead to 
specific pathological conditions. For example, iodine 
deficits can lead to cretinism, zinc to acrodermatitis 
enteropathica, Cobalt (Cyanocobalamin) to a compromise in 
myelin integrity (of neural tissue) and copper deficits to 
Menkes disease. 
There are several anecdotal reports (MacIntyre 1990, 
Shepherd, 1989) that link viral infections ( flu, sore 
29 
throat, swollen glands) with persistent feelings of 
illness when the virus concerned is not significantly 
eradicated. There are also reports that identify the 
persistence of illness feelings long after the patient had 
apparently recovered (Shepherd 1989). One implication of 
this finding is that the CFS syndrome may occur in people 
who have both with mineral deficits and have also suffered 
severe viral infections (e.g. the flu). The fact that the 
CFS sufferer seems to come from all walks of life (Lloyd, 
et al. 1990) might suggest, that the failure to recover 
quickly and completely from the condition may be due to a 
more basic health condition like mineral deficiency 
combined with a persistent viral infection. 
In England, Cox et al. (1991) have suggested that the 
syndrome shown by ME subjects may be due to magnesium 
deficiency. Hypomagnesemia is a magnesium deficiency 
condition caused mainly through malabsorption within the 
renal system or alimentary tract as a result of illness 
conditions like diabetes or some form of thyroid anomaly 
(Merck 1987). Having low magnesium blood levels (<1.6 
mEq/L) can lead to the development of complex nervous and 
muscular disorders similar to those seen in patients with 
serious hypocalcemia and hypokalemia. These disorders are 
also identified by symptoms (weakness, fatigue, muscle 
pain) similar to those seen in the CFS condition. 
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Cox et al investigated the possible importance of 
magnesium in a double blind, placebo/treatment trial with 
CFS and control subjects using intra-muscular magnesium 
injections. A pre-trial check on blood magnesium levels 
showed that CFS subjects were significantly lower in 
magnesium than the controls at the start of the trials. 
This study also found that CFS subjects were significantly 
improved in their feelings of well-being (using the 
Nottingham health profile). However, their blood 
magnesium levels increased with continued supplementation, 
as did their experience of well being during the course of 
the study. 
Another example of metabolic disturbance and muscular 
problems, in this instance muscle wasting, as a result of 
mineral deficits is recognized in the condition of 
Keshan's Disease. Keshan's Disease (Robinson 1988), is an 
endemic disease characterized by the presence of 
cardiomyopathy, muscle fatigue and pain. The disease is 
significantly linked to a very low Selenium level in both 
food and body tissue (Passwater, 1980) • Not 
surprisingly, successful treatment of this condition was 
achieved through Selenium supplementation (Thompson 1991). 
Further more this form of treatment once again stresses 
the importance of adequate mineral levels, but more 
important it high-lights the use of Selenium for 
maintaining good heal th. The problems of biological 
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disturbances arising from matters like vascular 
insufficiency, metabolic dysfunctions and mineral deficits 
are all likely to contribute to the general feeling of 
illness experienced by chronically ill patients including 
CFS sufferers. 
1.11 SELENIUM AND HEALTH 
The study of Selenium as an important mineral supplement 
has had many unexpected results. Al though the precise 
role of selenium in any pathological condition is still 
not clearly understood (Thompson 1991), researchers have 
found that selenium's role in the anti-oxidant enzyme 
Glutathione peroxidase (GSHPx) is important in avoiding 
oxidation stress within cells (Thompson, et al 1987). 
Oxidation stress occurs when lipid peroxidation and the 
build up of hydrogen peroxide, during metabolism, develops 
to the point of oxidizing cell enzymes and breaking down 
other cell proteins. GSHPx is a selenocysteine molecule 
( containing four atoms of selenium) that stops lipid 
peroxidation and converts harmful hydrogen peroxide to 
water. Selenium may also act as an extracelluar oxidant 
or agent of transport (Burk, 1989) within the body 
tissues. Animal experiments (Combs and Combs 1986) have 
also indicated a possible protective role of high selenium 
levels in animal tissue against the development of 
tumorigenesis. (No one yet knows the mechanism by which 
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that protective function operates - some even doubt its 
existence). Epidemiological studies have likewise 
suggested a protective role of high selenium levels in 
humans against the development of cancer and possibly 
cardiovascular diseases (Thompson 1991). These 
functional aspects imply a reduction in physiological 
stress when the selenium levels are high enough to 
maintain adequate GSHPx levels. What is not understood 
is the so called 'adequate' level of selenium in the body. 
As Thompson (1991) recently pointed out, the problem of 
defining deficiency or toxicity with respect to selenium 
(or any other element for that matter) is still beyond our 
capability to measure in any scientific or meaningful way. 
So far, we know what can happen at the two extremes 
(deficiency and toxicity), but how much is needed for 
maintaining good heal th remains a mystery. In fact, at 
this point in time, nutritional science does not yet have 
any means of determining the optimal or minimal mineral 
requirements for proper nutritional status. 
As already pointed out, so far we have little 
understanding about the role of the selenoenzyme GSHPx. 
But we do know that it does prevent oxidative damage 
arising from the build-up of peroxides in cells. 
Furthermore it is known that selenium does not operate on 
its own in cellular metabolism and Robinson lists a number 
of interacting factors including vitamins A, B, c, E and 
viral infections. An additional problem is the lack of 
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understanding about whether selenium plays a direct role 
in functional nutrition or is a limiting factor relating 
to enzyme activity. 
Another interesting finding with selenium is its role in 
thyroid activity, as part of a selenocysteine containing 
enzyme (Berry, Met al 1991). Evidently, the active role 
of thyroxine depends on the presence of Type I 
iodothyronine deiodinase (a selenocystein-dependent 
enzyme) to convert T4 ( Tetraiodothyronine) to T3 
(Triiodothyronine) in the on-going process of growth and 
metabolism. Berry et al. (1991) have shown that, in rats, 
a deficiency in selenium will upset this process and 
inhibit thyroxine activity. Since thyroxine activity is 
linked to the active process of metabolism, it seems 
reasonable to expect general well-being to be improved 
when levels of selenocystein enzymes are raised. 
One group of investigators (George and Walmsely - Princess 
Margaret Hospital) have recently postulated the 
possibility that lowering of thyroid activity 
(hypothyroidism) could increase hypercholesterolaemia (and 
possibly increase the chances of a heart condition). Part 
of the reasoning is based on the belief that people who 
generally experience more stress are also likely to 
develop eating disorders which may affect their level of 
thyroxine activity. People who suffer continual stress 
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are also likely to develop lower levels of wellbeing and 
may generally tend to put on more weight as a result of 
some physiological disorder associated with diet 
metabolism (George et al 1991). Again these people are 
thought to have lower levels of thyroxine activity which 
may cause higher levels of metabolic storage leading to 
serious weight gain and possible cardio-vascular problems 
Never-the-less, there is still no acknowledged medical 
condition currently in New Zealand that is related 
directly to deficiency in Selenium. 
1.12 RELATED PROBLEMS IN MEDICAL CARE 
A number of heal th issues seem to have no apparent 
explanation or reason and remain unresolved. The cot 
death rate in New Zealand is thought to be higher than in 
comparable western countries. The rate in Auckland is 
2.5/1000 live births and is comparable to that in the USA, 
UK and Australia. But the rate in Dunedin and 
Invercargill is three times higher than in Auckland. 
Further more the daily intake of Selenium in Dunedin is 
much lower (< 30 mcg) than is the case in Auckland. In 
analysing the population blood selenium levels and 
distribution of cot deaths, Logan (1988 pp 190) has found 
a strong inverse correlation between the population diet 
selenium levels and the incidence of cot deaths (SIDS) in 
New Zealand. Evidently a similar finding has been 
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uncovered in Southern Australia and Tasmania (Logan 1987). 
Logan also points to the hypothesis of Money (1970) which 
suggested that selenium may be an important factor in the 
Sudden Infant Death Syndrome (Logan 1987). 
Despite the numerous anomalies and various unexplained 
heal th issues, Keshans' disease is not found in New 
Zealand. However, the major symptoms of CFS are myalgia 
and persistent fatigue. These symptoms would suggest a 
possible link between low Selenium levels and the general 
condition of CFS. 
In the following section, we will discuss the scientific 
data relating to selenium and its possible effect on both 
the New Zealand population and other groups elsewhere in 
the world where low selenium levels are found. 
1.13 SELENIUM IN NEW ZEALAND 
Like many parts of Britain, New Zealand also has vast 
agricultural areas with low level selenium soils. 
Scientific reports as far back as the early 1960's 
(Watkinson 1962) have indicated a marked deficiency of 
selenium in New Zealand soil (Fig 1). This problem is 
accentuated in the South Island and in particular the East 
coast including most of the Otago region (DSIR 1965). 
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Fig. 1 MAP: THE MAIN SELENIUM DEFICIENT REGIONS OF N.Z 







According to Watkinson (1981), the New Zealand pattern of 
selenium deficiency seems to follow a north-south 
gradient where Aucklanders' selenium intake is higher than 
for those who live in Dunedin or Invercargill (see Fig 2 
table). In the south-east parts of the South Island, 
residents are likely to have a selenium intake of less 
than 35mcg/daily (Thomson and Robinson 1974). Thompson 
and Robinson (1988) have also shown that locally grown and 
processed food reflects this low level (<0.05 mg/kg soil) 
of selenium. This low selenium content in the Otago 
region in particular, affects the food chain to the extent 
that food grown there provides less selenium for the food 
material used in human diet. 
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Fig 2. Table - Blood Selenium levels in healthy adults in 
5 different countries 
81o(xj Seleri\Jll of Healthy Adults 









no.of subjects • (210) (250) (6) (25) (8) (122J(ll4Xfil) 
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People in Otago experience a low selenium intake ( 25 
mcg/d) from locally grown food resulting in low (< 0.01 
mcg/ml) blood selenium levels (Thompson and Robinson 
19 8 8 ) . Thompson also points out that but for the 
importation of Australian wheat, people in the North 
Island would also be experiencing low blood selenium 
levels. 
Recently another report (Winterbourne et al 1992) has 
indicated an overall rise in blood Selenium, from 50 mcg/L 
- 90 mcg/L, ( See fig. 3) for the general population of 
Christchurch based on the increase of diet Selenium since 
the importation of higher Selenium wheat for the 
Canterbury flour mills from Australia; (the average 
Selenium content of blood in Christchurch New Zealand is 
between 40 and 50 mcg/L). Although the reason for the 
importation of wheat (See fig.4) is both commercial and 
political, there is no doubt that the health authorities 
are pleased with the trend and are hopeful of seeing an 
















Fig 3. Changes in Plasma Selenium Found in Christchurch 
Adults in the Period from 1981 - 1992, (Winterbourne, 
1992) 












































Fig. 4 South Island Wheat Production and Imported Wheat 
as a percentage of Total N. z. Wheat, From 1981 - 1991 
(Winterbourne, 1992) 































Tapanui, in south Otago, is a large rural region in the 
middle of a low soil selenium area in the South Island of 
New Zealand. Snow ( 1982), a GP in Tapanui, was the 
first to alert the health authorities on the development 
and increasing incidence of CFS (locally referred to as 
"Tapanui flu") in New Zealand. Through his concern for 
the unexplained suffering of many of his CFS patients, 
Snow was able to involve the medical research team in 
Dunedin ( at the school of Medicine) to investigate the 
possibility of mineral deficiency and other matters 
relating to the plight of CFS sufferers. In the 
following discussion, we will examine closely the possible 
link between Selenium supplementation and feelings of 
well-being as shown in results from recent studies. 
1.14 HEALTH, WELL-BEING AND SELENIUM - A STUDY OF EFFECT 
It has already been pointed out that people who sometimes 
complain of being run-down and seemingly have no energy 
may be experiencing some kind of stress that may be 
related to or exacerbated by mineral deficits. It has 
been argued that selenium levels can affect thyroid 
activity which in turn can change our mood states (Berry 
et al 1991). In addition Passwater ( 1980), has argued 
that stress related to mineral toxicity arising from 
environmental pollution is decreased by the use of 
selenium supplementation. (Selenium is thought to replace 
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the more harmful minerals that can otherwise cause enzyme 
or protein destruction). The concern with low selenium 
levels in soil and food has been around for many years and 
some South Canterbury and Otago farmers have been known to 
consume the selenium product (sodium selenite) they use to 
drench their sheep and cattle (Trotter, B 1978, Robinson 
1975). 
A major health problem with stock in the south island is 
a collagen defect in muscle development called white 
muscle disease arising from insufficient selenium in stock 
food. White muscle disease causes stock to become lame 
and develop sores like those caused by infections. 
Furthermore, Watkinson (1962) had pointed out that sheep 
grazed on depleted soils with less than 0.5ppm selenium 
had a high incidence of selenium-responsive diseases. 
Many farmers in these selenium depleted regions believed 
their aches and pains were equivalent to the muscle 
problems of their stock (Trotter, B 1978). Further more 
they believed these symptoms would be alleviated by the 
use of selenium supplementation (Thompson 1991) in the 
same way that white muscle disease was overcome by 
selenium supplementation in animals. In 1981 Snow and 
others (Robinson et al 1981) at the School of Medicine 
(Otago University) reported a study that is particularly 
relevant to the present thesis. 
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The report was based on a study of the effect of selenium 
supplementation on subjects initially diagnosed as having 
painful experiences with fibromuscular rheumatism. This 
fatigue-like experience was one of the early symptoms 
later identified by Murdoch as typical of the CFS 
syndrome. The study involved different groups of patients 
in three separate trials over three different time spans 
(Tapanui-1974,Tapanui-1975,Tapanui-Christchurch-Gore-1977-
1978) and involved what appeared to be separate groups of 
medical physicians in the different locations. Subjects 
for this study were selected on the basis that each 
presented the symptoms of muscular complaints (pain and 
fatigue) without any apparent cause that the examining 
physician could identify. 
Treatment consisted of different levels and forms of 
selenium compounds (mineral selenite or organic 
selenomethionine) in varying durations. The three 
trials were identified as trial A ,Band C (1974, 1975 and 
1977-1978 respectively). 
In trial A, 20 patients fitting the clinical criteria of 
having muscular 
rheumatism, were 
complaints, as in fibromuscular 
given a daily dose of 500 mcg sodium 
selenite in liquid form for twenty days. 
In trial B, 24 patients ( 10-60 yrs) fitting the same 
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criteria were selected for testing. Twelve were given a 
5 ml solution of semet-selenium ( organic selenomethionine) 
and the other 12 a 5 ml placebo for 12 weeks on a double -
blind trial. Selenium blood tests on all patients were 
carried out before taking treatment and then every two 
weeks thereafter. A final blood test was carried out 8 
weeks after the final dosing to determine any significant 
changes. 
In trial C 78 patients (29 from Tapanui, 37 from 
Christchurch, 12 from Gore) were given a capsule of 90mcg 
selenite selenium mixed with 20/10 vitamin E or a placebo 
in a double blind trial. 
Assessment of each of the above treatment was made in two 
ways. The objective method required the physician to 
record signs ( or lack of them) of improvement in symptoms 
that were diagnosed earlier in each subject. The 
subjective technique relied on physician and patient both 
rating the level of improvement as they felt at the time 
of interview, using a 0 - 3 four point rating scale (0 
being complete resolution of all symptoms and 3 = no 
improvement or worsening of symptoms). 
Using the above criteria, collected data from trial A 
showed ten subjects had improved and ten did not. In 
trial B, the overall result of the clinical assessment of 
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symptoms indicated 11 had recovered and 12 were unchanged. 
In trial c, again no significant difference between the 
group on placebo and the group on selenium could be 
found ( 38 recovered, 39 did not). In all three trials, 
subjects on selenium showed a significant increase in 
blood selenium levels compared to those on Placebo. 
However, there are problems raised about the efficacy and 
validity of certain aspects of the study. 
Although the aim was to investigate the alleged beneficial 
effect of selenium supplementation (reported by some 
farmers) , there was no attempt to examine the 
psychological profile of patients who complained of the 
unexplained muscle pain and fatigue. It is difficult to 
see how the impact of treatment could be measured 
effectively if the assessment was limited to a criteria of 
observing symptoms (muscular) being present or absent at 
the time of interview using a relatively crude rating 
scale that concentrates only on "muscle weakness". The 
evaluation was also carried out by multiple examiners for 
separate groups. 
Hence the issue of varying levels of body selenium and 
the effect that might have on mood levels of CFS subjects 
is one that still needs to be carefully investigated. To 
understand how subjects with CFS are affected requires a 
knowledge of their mood profiles and the way their mood 
might change in relation to blood selenium levels. 
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1.15 SELENIUM AND MOOD CHANGE 
Benton and Cook (1990) in Wales have also noted that there 
were low levels of selenium in both food and soil in 
Britain. What was equally important was the trend towards 
a lowering of this level in England due to a greater 
reliance on locally grown products rather than imported 
wheat from Canada with its much higher selenium content. 
This being the case, Benton points out that an average 
intake of 43 mcg/day in Britain is well below the 
recommended level of 50=200 mcg for adults. The 
possibility of health in general being affected by this 
low level was examined in the following investigation. 
1.16 THE BENTON/COOK SELENIUM INVESTIGATION AND THE 
PRESENT STUDY 
Benton and Cook (1990) investigated the role of selenium 
supplementation on the mood states of a university 
population living in Wales (UK). In this study 17 males 
and 33 females (age 22-54) were given 100 mcg of selenium 
or the yeast placebo supplement in the form of a tablet 
taken once a day for five weeks, using a double-blind, 
cross-over design. 
Before the treatment began, at week 2.5, and at the end of 
week 5, all subjects were given the Bi-Polar Profile Of 
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Mood States (POMS, Lorr and McNair, 1982) questionnaire to 
complete. At the end of the first five week period, 
subjects were put on a six month wash out tablet-free 
period. At the beginning of the second five week period, 
subjects' mood was again reassessed and each subject given 
the alternate tablet for the second five week period. 
The results indicated that selenium supplementation was 
responsible for increasing mood scores. Subjects on 
placebo did not show any significant change in their mood 
score. The conclusion was that mood scores improved over 
time when selenium ( rather than placebo) was taken by 
subjects. 
In a subsequent follow up study Benton and Cook ( 1991) 
further concluded that selenium deficiency in the British 
diet is closely related to lower levels of well being and 
that raising selenium intake promotes a higher level of 
well being for their subjects. In this investigation 
(Benton and Cook 1991), the food intake of all subjects 
was monitored by way of interviews and food frequency 
questionnaires. From this information they selected 
subjects who were on "high" as opposed to "low" levels of 
selenium food intake. When given selenium 
supplementation, subjects on low diet selenium showed a 
significant increase in mood score. But more important, 
subjects with low dietary selenium showed a more 
significant increase in mood score. 
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This means that 
people with low selenium intake may have a greater need 
for selenium. It is clear from Benton and Cook that 
selenium has a role to play in the mood levels and 
possibly the experience of well being in subjects. How 
selenium affects mood is not clear. But one interesting 
speculation relating to iodothyronine (Berry et al 1991) 
was discussed earlier on. Never the less it is a well 
known fact that hypothyroidism is characterised by 
symptoms of mood apathy and retarded speech (Rosenzweig 
and Leiman 1989, Merck 1987). In more severe iodine 
deprivation, the syndrome called Myxoedema begins to 
emerge and the symptoms of fatigue, weakness, aching 
muscles and cramps become more prevalent (Houston et al -
A Short Textbook of Medicine 1968). But obviously, and 
from Benton and Cooks'(1990,1991) results, mood elevation 
can be linked to selenium supplementation and if that is 
true, then perhaps the converse (low selenium) might be 
a partial explanation for having lower mood levels. The 
diagnosis of depressive mood levels in CFS sufferers is a 
common feature of the CFS syndrome. 
In the current study, it is also speculated that selenium 
may play some part in controlling mood changes in CFS 
subjects. The present study, therefore, but in the 
context of another (i.e 'healthy' New Zealanders) 
population, attempted to replicate in part the Benton and 
Cook (1991) study and further more to examine the question 
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of whether selenium supplementation may also have an 
effect on subjects who have been diagnosed as CFS 
sufferers. 
From the foregone discussion it should be clear that the 
major question for the present thesis is the effect of 
selenium supplementation on the well-being of those 
suffering from CFS and a healthy comparison control. In 
this study, the main aim was to examine carefully the 
effect of selenium supplementation on both CFS and non-CFS 
subjects. But we were also interested in the relative 
differences between the two groups of subjects and in 
particular whether the normal controls could reflect the 
impact of selenium on mood as was shown by Benton and Cook 
in their investigation. 
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Chapter 2 METHODS 
2.1 SUBJECTS 
Only CFS subjects diagnosed by Professor Murdoch, using 
the criteria listed pp 5, were considered for the CFS 
group in this study. Furthermore, we excluded those who 
had other illness conditions or may have suffered any Non-
CFS neurological, psychiatric or psychological 
disturbances (see table - appendix). The controls were 
selected on the basis that they were free of any past or 
present major medical or psychiatric illness condition. 
In total, thirtyseven CFS subjects (8 males, 29 females) 
invited took part in a placebo controlled study. Each CFS 
subject was matched (age, sex, socio-economic status and 
ethnic origin) with a healthy non-CFS control. The age 
range was 23-55. (see Fig. 5 and 6). 
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Fig. 5 
Group: mean age and standard deviation 
GROUP X TREATMENT Mean Age S.D 
Healthy Controls/ placebo 37 11 
Healthy Controls/ selenium 39 10 
CFS/ placebo 37 11 
CFS/ selenium 40 10 
Fig. 6 
Group Size 
GROUP TREATMENT SAMPLE SIZE 
Healthy Controls Placebo 18 
Healthy Controls Selenium 19 
CFS Placebo 14 
CFS Selenium 19 
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Each matched pair was randomly assigned to one of two 
treatment (selenium/ placebo) groups and given the same 
treatment throughout. A few subjects who initially 
started in the study withdrew for a variety of reasons. 
Three controls found the study requirements too 
difficult to adhere to. Two CFS subjects became too ill 
to continue. One CFS subject who felt well on the 
treatment (i.e reduced muscular pain and arthritic 
inflammation) found she was experiencing a 'high' she 
could not cope with. A week after she refrained from 
taking the tablet (which incidently was selenium) she 
reported feeling 'normal' again - and was much happier 
for it. 
In the final analysis, thirty three CFS subjects and 
thirty seven controls completed the trial. 
The selection of subjects was carried out during the 
late summer period (January-February 1991). A 
noticeable feature of the CFS group, was the high 
incidence of unemployment, perhaps a testimony to the 
severity of the syndrome (and economic stress) in the 
Otago-South Canterbury region of New Zealand. 
All subjects who took part in this study were personally 
interviewed by the present author and each gave 
informed, written consent and was made aware of their 
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right to withdraw at any time they felt it necessary. 
During the interview an overview of the whole programme 
was outlined including what was required of each 
subject. An information sheet containing this summary 
was given to each prospective subject.(see appendix). 
Ethical approval for the present study was obtained from 
the Canterbury and Otago Area Health Boards, and the 
Human Research Ethics Committee of the Department of 
Psychology at Canterbury University. 
2.2 TREATMENT PROTOCOL 
Treatment comprised of a selenium tablet containing 150 
mcg of selenium (as selenomethionine) in a yeast-free 
base, or an appropriate neutral placebo that had no 
selenium (supplied by Vitafit Megavitamin laboratories-
Christchurch). The chosen level of 150 mcg selenium was 
based on the literature (Robinson 1988, Thompson 1991, 
Spallholz 1989) suggesting that levels of 
supplementation between 100 and 200 mcg would be 
sufficient to effect an increase in blood selenium 
levels of treated subjects. Our six week trial period 
also had sufficient duration for the body to adapt and 
adjust to the increase in selenium treatment. 
Subjects were matched and paired and each pair was 
randomly allocated to a treatment condition (Selenium or 
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placebo) such that each CFS subject and the 
corresponding Non-CFS control were subject to the same 
treatment condition at the same time. 
We were careful not to employ any material in the 
treatment (or placebo) that may exacerbate the symptoms 
of our CFS volunteers. One important aspect of the CFS 
condition is the sensitivity of many of these subjects 
to yeast, cereals and dairy products. Hence, both 
tablets were made from cellulose with the minimum of 
calcium and magnesium binder added to create a 
homogeneous form that would make one tablet 
indistinguishable from the other. Subjects were also 
advised that should a tablet be forgotten on one day 
that a maximum of two should be taken the following day. 
To help subjects and as a memory aid, each was also 
given a specially designed wall calender that actually 
indicated the start, finish, blood testing and mood 
testing dates of the trials, plus a calender for 
checking whether the daily tablet had been taken, was 
affixed to the tablet bottle. 
Subjects who were willing to do so, presented themselves 
for a blood test that involved the removal of a 5-10 ml 
sample of blood. The blood tests were done just prior 
to the commencement of the treatment trial and 
immediately following the conclusion of the sixth week 
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(All blood samples were collected in a hospital or a 
medical laboratory). Subjects were informed that a 
blood test was not critical to ongoing participation in 
the trials although it was pointed out that we did 
require some blood checks to verify the pre and post 
trial selenium levels of subjects in general. 
The taking of blood samples from subjects was done by 
experienced medical staff at the Hospital Laboratories 
in Dunedin, Oamaru, Timaru and Princess Margaret 
Hospital in Christchurch. Biochemical analysis of 
plasma selenium was performed by Mr Walmsley at the 
Biochemistry Department of Princess Margaret Hospital 
using a standardised carbon furnace spectrophotometer 
procedure developed at Christchurch Hospital. Plasma 
selenium is regarded as an effective measure of changes 
in selenium status (Thompson 1991). About two thirds of 
all subjects underwent blood tests both at the pre and 
post trial periods of the six week trial. 
2.3 EVALUATION PROTOCOL 
Subjects mood changes were measured by two sets of 
questionnaires. These were the Beck Depression 
Inventory- BDI, (Beck and Steer, 1987), and the Profile 
Of Mood States (POMS)- Bi polar form (Lorr and 
McNair,1982) Each set was completed just before the 
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tablets were started, at the end of week three, and at 
the end of the sixth week of the trial. 
At each testing, subjects were in small groups of from 
10 to 15. (depending on location). On each occasion, 
subjects were given the POMS followed by the BDI. In 
each case a set of instructions for each questionnaire 
was read to the group detailing the way that particular 
questionnaire should be answered. Subjects were then 
advised to read carefully the instructions on the front 
of the questionnaire and to ask any questions about 
matters they were still unclear about. One major 
problem that some subjects had difficulty with was the 
ability to conjure up an average perception of the past 
week and then be able to rate it according to the 
immediate question. It was explained that the main 
point was how they perceived of the week as a whole 
rather than just one day that may have been stressful 
or pleasant. When these matters were sorted out to the 
satisfaction of all concerned, the group were asked to 
start. Some specific instructions for each test are 
outlined in the following description of the two 
questionnaires. 
(Sample questionnaires can be found in the index) 
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2.4 BECK DEPRESSION INVENTORY (BDI) 
The BDI was scored by adding up the 21 ratings (0-3) 
made by subjects. The score range is 0-63. A high 
score would indicate a severe level of depression. A 
few subjects found the language difficult and had to 
concentrate to get through the questionnaire. 
2.5 PROFILE OF MOOD STATES (POMS; BI-POLAR) - 1980 
EDITIONS 
The use of this questionnaire followed the guide lines 
provided by the manual. The questionnaire consists of 
72 adjectives describing feelings and different moods. 
Subjects indicate how they have been feeling over the 
past week by ticking a point on the four point scale -
much unlike this; slightly unlike this; slightly like 
this; much like this. McNair et al (1971) have 
suggested a total mood score can be calculated so that 
those with a high score are composed rather than 
anxious, agreeable rather than hostile, elated rather 
than depressed, confident rather than unsure, energetic 
rather than tired and finally clearheaded rather than 
confused. 
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Each of the adjective pairs reflects one of the six 
component bipolar mood states measured by twelve of the 
adjective check list of 72 adjectives. 
2.6 DATA ANALYSIS 
Total mood scores from the three questionnaires were 
subjected to an analysis of variance with Group (CFS vs 
Non-CFS) and Treatment (selenium vs placebo) as the two 
between subject factors and Time (0vs3vs6 Weeks) as the 
repeated measures. The six subscores from the POMS and 
the BDI scores were also subjected to a similar analysis 
of variance. A two level repeated measure for time ( 0vs6 
Week) was used for the Blood selenium data. These 
univariate analyses were carried out using a general 
Manova package (CSS;Statsoft). 
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Chapter J RESULTS 
3.01 BLOOD SELENIUM LEVELS 
The results from blood tests (Fig 7) revealed that blood 
selenium levels in both groups of subjects was generally 
low, as expected (Robinson 1988). However, they also 
showed that the low selenium levels in CFS subjects were 
not significantly different from the low levels in their 
Control counter-parts at the start of the supplementation 
trial (F<l.O). Blood Selenium levels showed a significant 
increase following supplementation (Treatment (Selenium vs 
Placebo) X Time interaction, F=27.74,df=l,44,P<0.0001) and 
there was a significant interaction between Group (CFS vs 
Controls) x Treatment x Time (F=4.66, df=l;44, P<0.05). 
When we examine each group separately, there was a Group 
X Treatment interaction for controls 
(F=4.49;df=l,44;P<0.05), but a much clearer increase in 
blood selenium levels was evident in the CFS group 
(Treatment X Time, F=29.82;df=l,44;P<0.0001). Thus CFS 
subjects appeared to respond to Selenium supplementation 
more than did the Controls (Group X Time interaction for 
selenium treated subjects, F=4.98;df=l,44;P<0.05). 
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Fig. 7 Plasma Selenium Levels Measured in Both CFS and 
Control Subjects 
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3.02 PROFILE OF MOOD SCORES FOR CFS AND CONTROL SUBJECTS 
The profile of mood states for the two groups at the 
beginning of the trial ( 0 week) is shown in figure 8. 
These 6 measures were subjected to a 2(CFS vs Control) x 
2(Selenium vs Placebo) X repeated measure of 6 component 
mood scores. The mean total mood score for CFS subjects 
was considerably lower the than mean total mood score for 
Control subjects (Group main effect, 
F=60.75;df=l,66;P<0.0001). However, the-re was no 
difference between subjects who were to be given selenium 
as opposed to placebo (Treatment effect, F<l.O; Group x 
Treatment interaction, F=l.6;df=l,66;P>0.10). 
There was a significant main effect of mood measure 
(F=40.44;df=5,330;P<0.0001). However, the profile of mood 
scores was different between the two groups as shown by 
the highly significant Group X Component mood score 
interaction (F=7.19;df=5,330;P<0.0001). For Control 
subjects the measure of composed-anxious, agreeable-hostile 
and clearheaded-confused were equal but were higher than 
elated-depressed, which was greater than confident-unsure 
and energetic-tired measures; the latter were similar. In 
contrast, the measure of agreeable-hostile was higher than 
all other measures whereas energetic-tired was by far the 
lowest, even relative to the confident-unsure measure. 
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3.03 EFFECT OF SELENIUM ON TOTAL MOOD SCORE 
Fig. 9 shows total mood scores for CFS and Control 
subjects given Selenium or Placebo in the 6-week trial. 
The total mood scores for the two control sub-groups are 
higher than the mood scores for both CFS sub-groups (main 
effect for Group, F=84.70;df=l,66;P<0.0001). The main 
effect of Treatment (selenium vs placebo) just failed to 
reach significance (F=3.49;df=l,66;P<0.06). However, the 
difference in total mood scores over time for the two 
groups is significant (main effect of 
Time,F=6.43;df=2,132;P<O.Ol). There were no significant 
interactions for Group x Treatment or Group X Time, but 
there was a suggestion of an interaction for Treatment X 
Time F=2.37;df=2,132;P<0.10) and, more importantly, 
there was also a suggestion of an interaction for 
Group(CFS vs Control) X Treatment (Selenium vs Placebo) X 
Time (F=2.45;df=2,132;P<0.10). 
Given the suggestion of this three way interaction, a 
planned comparison of the Treatment by Time interaction 
for the CFS group and the control group separately was 
carried out. These analyses revealed that the Treatment 
by Time interaction for control alone was not significant 
(F<l.O) but, by contrast, there was a significant 
Treatment by Time interaction (F=3.8l;df=2,132 ;P<0.05) 
for the CFS group. The simple main effect of Time for 
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CFS/Placebo sub-group was not significant (F<l.O) whereas 
the simple main effect of Time for the CFS sub-group 
taking selenium was highly significant 
(F=8.64;df=2,132;P<0.001). In addition, the increase in 
total mood scores in CFS/Selenium subjects was 
statistically significant between both O week vs 3 week 
test(F=4.40;df=l,66;P<0.05) and 3 week vs 6 week test 
(F=4.55;df=l,66;P<0.05), and total mood scores of CFS 
subjects on Se were different from the total mood scores 
of their CFS counterparts on placebo at week 6 ( simple 
main effect of treatment at week 6, 
F=7.96;df=l,66;P<O.Ol). weeks). 
An examination of the individual scores in the CFS/Se 
group revealed that 16 of the 19 CFS/Se subjects improved 
their total mood scores during Se treatment. Twelve of 
these subjects reached a score of 140 or better by week 6. 
This means 64% of CFS subjects on Se treatment showed an 
improvement that saw their mood levels elevated to the 
same pre-treatment level shown by controls. 
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3.04 COMPOSED-ANXIOUS SCORES 
These data are shown in Fig. 10. CFS subjects had a lower 
score on this measure (main effect of Group, 
F=50.17;df=l,66;P<0.0001). There was also a treatment 
main effect, subjects on selenium scored higher than on 
placebo (F=3.9l;df=l,66;P<0.05). No other effects 
approached significance except the Treatment X Time 
interaction (F=2.31;df=l,132;P<0.10). The placebo groups 
did not change over time, but there was an indication that 
selenium groups improved over time 
(F=3.54;df=2,132;P<0.05). 
3.05 AGREEABLE-HOSTILE SCORES 
These data are shown in Fig. 11. The only significant 





and a Time main ef feet 
No other effects approached 
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3.06 ELATED-DEPRESSED SCORES 
These data are shown in Fig. 12. There was a significant 
Group main effect (F=53.98;df=l,66;P<0.0001) and a 
significant Time effect (F=5.93;df=l,66;P<O.Ol) but the 
main effect for Treatment failed to reach significance 
(F=3.33;df=l,66;P<0.1). The Group X Treatment X Time 
interaction was significant (F=4.02;df=2,132;P<0.02). As 
shown on graph, the selenium/control group was higher than 
the placebo/control group at O weeks, but the·CFS/Selenium 
group was higher than the CFS/placebo at 6 weeks. 
However, the Treatment X Time interaction for the CFS 
groups did not reach significance(F=2.68;df=2;P<0.07). 
3.07 CONFIDENT-UNSURE SCORE 
These data are shown in Fig. 13. The only notable effects 
were that CFS scored much lower than controls 
(F=66.45;df=l,66;P<0.0001) and a highly significant 
increase in scores over Time(F=8.64;df=2,132;P<0.001). 
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Fig. 13 The Confident - unsure Subscore for CFS and 
Control 
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3.08 ENERGETIC-TIRED SCORE 
These data are shown in Fig. 14. There was a significant 
main effect for Group (F=l45.96;df=l,66;P<0.0001), no main 
effect of Treatment (F=2.23; df=l,66; P>0.10) and an 
increase in score over Time (F=5.9l;df=2,132;P<O.Ol). 
However, there was also a Treatment X Time interaction 
(F=4.08;df=2,132;P<0.02). Analysis of the simple main 
effects of this interaction showed an increase in mood 
score in the selenium Group only (P<0.01). 
3.09 CLEARHEADED-CONFUSED SCORE 
These data are shown in Fig. 15. There is a main effect 
for Group(F=60.03;df=l,66;P<0.0001), a main effect for 
Time (F=3.95;df=l,132;P<0.05) but the main effect for 
Treatment was not significant (F=3.35;df=l,66;P<0.07). 
There was an indication of a Group X Time X Treatment 
interaction(F=2.44;df=2,132;P<0.10). There was no 
Treatment X Time interaction for controls(F<l.O) but there 
was one for CFS subjects (F=3.97;df=2,132;P<0.05). 
Selenium CFS subjects showed a highly significant increase 
in mood scores over Time(F=8.69;df=l,132;P<0.001). 
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Fig. 15 The Clear Headed - Confused Subscores for CFS and 
Control 
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These data are shown in Fig. 16. CFS subjects scored 
considerably higher than controls on the BDI. Analysis of 
the BDI scores revealed a significant main ef feet for 
Group (F=72.55;df=l,64; P<0.0001). Although there was a 
slight indication that CFS subjects on selenium had 
reduced scores by week 6 compared to CFS subjects on 
placebo, the only other significant effect was a Time main 
effect (F=8.07; df=2,128;P<0.001) due to scores improving 
for subjects as a whole over weeks. 
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Fig. 16 Mean BDI Scores for CFS and Control 
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Chapter 4 DISCUSSION 
4.1 DIFFERENCES BETWEEN CONTROL AND CFS SUBJECTS 
Consistent with previous findings reported by Hickie et al 
(1990), Manu et al(l989), Kruesi et al (1989) and Taerk 
(1987) that CFS subjects are more likely to show 
depressive symptoms, CFS subjects in the present study 
also reported higher levels of depressive symptoms as 
measured by the Beck Depressions Inventory. Indeed Abbey 
and Garfinkel (1991) suggest that CFS subjects may 
represent a subgroup of depressive patients. 
General mood states, however, have not been reported for 
this group before. The mean total mood scores for the CFS 
group was found to be low (90) and according to the manual 
(Lorr and McNair 1982) was much lower than the average of 
144 obtained from an unselected group of presumably 
heal thy subjects. The heal thy control subjects in the 
present study had a mean score of 156 at the start of the 
study. In addition there was a difference in the profile 
of mood states between CFS and Control subjects. The 
component levels for CFS subjects are all relatively low 
compared to those for controls, but subjects are 
particularly likely to report more tired than energetic 
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and more unsure than confident. 
4.2 EFFECTS OF SELENIUM IN CONTROLS 
Benton and Cook (1990) reported that healthy subjects on 
selenium supplementation showed a clear and significant 
improvement in their total mood scores. In the present 
study however, there was no significant change in total 
mood score in controls on selenium and there is only a 
weak suggestion of mood improvement from the analysis of 
subscores for the composed-anxious and energetic=tired 
measures. Benton and Cook ( 1991) also reported that 
subjects on low diet selenium are likely to show an 
improvement in mood score following selenium 
supplementation. However, controls in the present study 
showed low selenium status as evidenced by the blood 
measures. Perhaps subjects in Benton and Cooks study had 
other mineral/vitamin deficits that had to be compensated 
for by selenium unlike those subjects in the present 
study. 
4.3 EFFECT OF SELENIUM IN CFS SUBJECTS 
There was a very marked mood response by CFS subjects in 
this investigation of selenium supplementation . The 
change in mood improvement for CFS subjects given selenium 
was similar to the response found by Benton and Cook with 
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healthy subjects in Wales. However, although the level of 
improvement made by CFS subjects in the present study did 
not attain the level achieved by Benton and Cook's (1990; 
1991) healthy subjects when taking selenium, they reached 
a level comparable to the mood scores shown by the healthy 
controls that were tested in this study. 
However, it also has to remembered that the mood profile 
of CFS subjects is different from normal subjects and may 
have led to some differences in response to 
supplementation. The only reasonable indication that mood 
improved in controls in the present study was on the 
energetic-tired score, where as CFS subjects showed 
improvement on all except the agreeable -hostile score. 
Both controls and CFS subjects in the present study showed 
the characteristically low blood selenium level found in 
most New Zealand inhabitants and further more the blood 
level in both groups prior to treatment was the same. 
The ref ore it seems unlikely that low levels are in any 
simple way was responsible for the CFS syndrome. Perhaps 
the use of selenium only alleviates the symptom complained 
of rather than provides a cure. However, it was 
noticeable that blood selenium levels in CFS subjects 
increased much more than was seen in controls on selenium. 
This raises the possibility that a greater amount of 
selenium is needed by CFS subjects to perhaps reduce their 
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symptoms or that the controls used here did not obtain 
high enough levels of selenium to elevate their mood 
scores. In the absence of any blood results, one can 
only speculate that Benton and Cooks subjects had higher 
blood selenium levels than those expected in New Zealand 
subjects (the average New Zealander has lower blood 
selenium than the average British subject) and that their 
blood levels rose considerably after taking selenium. 
There may also be other important mineral factors as 
evidenced by the response of a British group to magnesium 
supplementation (Cox et al, 1991). 
When the present findings are compared to results from 
other studies that used selenium supplementation, other 
interesting differences appear. The investigation by 
Robinson et al (1981) did not find any evidence of 
improvement in symptoms of muscular pain and tiredness 
following selenium supplementation in CFS subjects. But, 
in the present study, the monitoring of CFS mood revealed 
a significant improvement in the well-being of CFS 
subjects that were treated with selenium. This difference 
in response may suggest a somewhat subtle mineral effect 
with respect to subjects who experience lowered mood 
states as a result of a decline in other areas of health. 
4.4 THE PRESENT STUDY AND ITS LIMITATIONS 
The present study has shown evidence that selenium can be 
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beneficial to the well-being of CFS subjects in terms of 
raising mood levels. With regard to selenium 
supplementation, this investigation is in part a 
replication of Bentons results, but only with respect to 
the CFS group. However, this type of study, involving 
selenium and CFS has not been undertaken elsewhere and it 
may be prudent to await confirmation before placing too 
much emphasis on the results so far discussed. 
But there is also a need to investigate other minerals and 
vitamins, the effect of varying these as well as the 
precise effect these minerals might have on the well-being 
of CFS and healthy subjects. 
It would also be important to consider different areas of 
wellbeing e.g memory and motor deficits found in both CFS 
(recorded by Smith, 1992) and perhaps healthy/ageing 
subjects discussed by Benton and Cook (1991). This type 
of investigation can be useful in identifying some of the 
basic problems displayed by some of the symptoms of CFS 
and perhaps healthy subjects. 
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CFS SUBJECT'S/ DURATION AND HISTORY OF ILLNESS 
Reported factors that may have precipitated Chronic Fatigue Syndrome 
CODE AGE yr 1st sign History 
1E 37 1.5 kidney stones, headaches, sensitive to noise & temo. 
2E 36 3 migraines kidney stones, sleepless 
3E 43 6.5 flu muscls fat. mental stress 
4E 26 4 flu fatigue allergies,sleeoless 
SE 42 11 stress migraines, allergies 
6E 43 8 toxic soravs glan.fever bowel irrit. 
7E 45 8 nausea,fatigue,caesar 
8E 46 4 headaches fatigue, headaches 
9E 18 10 from parents asthma, allergies 
lOE 43 3 fatigue headaches 
llE 44 8 allergies, fatigue 
13E 29 3 flu'79 tonsils aged 4 
14E 43 7 fatigue, depress. headach. sleep! 
lSE 44 3 blood tran. Hysterect '84 
16E 38 2.5 glan.fever kidney stones, arthritis, hepatits, pneum.appendic. 
19E 49 2 famil trauma sleeplessness 
21E 58 6 virus sprays arthritis bronch.mumps,etc 
22E 36 14 virus chicken pox meas.mumps allergic penicilin, oranges. 
sleeplessness 
23E 52 fatigue, mem.loss, irr.bowel depression, visual disturb. 
24E 43 9 virus sinus allergies 
25E 19 4.5 gland. fever bow.irr 
26E 42 2.5 mental fatig sleep!. memory loss 
28E 29 8 muscl.disor. gallbladder,glan.fever 
29E 41 1 asthma, tonsils,PMS allerg. 
30E 30 3 Leptospirosis, ashthma 
32E 20 o.5 bronchitis disturbed sleep. 
33E 32 3 allergies, sleeplessness 
TABLE: (cont.) 
CFS SUBJECTS I HISTORY OF ILLNESS 
CODE AGE vr 1st sign Historv 
35E 33 5 glan.fever Hp virus fatigue, sleepl. 
39E 50 8 lead poisoning Eng.measles, flu, chicken pox mumos sleeplessness 
40E 54 3.5 stress, g, fever scarlet fever, mumps, chicken pox .pneumonia, depression 
41E 46 5 car acci. stress sleeplessness allergies 
46E 22 5 glan.fever sleepless, allerg. mem.loss 
48E 23 6 virus aooendicitis, stomach probl. 
49E 35 6 tonsil, allerg. mood changes 
SOE 40 6 gland.f.ovarian cysts 
Department of Psychology 
University of Canterbury Christchurch New Zealanc 
Telephone: (03) 667-001 
Fax: (03) 642-181 
DEPARTMENT OF PSYCHOLOGY UNIVERSITY OF PSYCHOLOGY 
CONSENT FORM 
Brief Description of Project: 
This project will investigate the possible influence of a mineral 
supplement on various mood states and levels of fatigue, using simple 
standard questionnaires, in a group of people who have been diagnosed as 
suffering from a chronic fatigue syndrome called Myalgic 
'Encephalomyelitis (ME) and in a group of healthy, non-ME subjects. 
Risks Associated with Participation: 
The mineral used is a naturally occurring one that will be in an 
otherwise neutral tablet (e.g., no yeast or vitamins) . The proposed 
quantity of daily mineral intake is well.within safe recommended limits 
for maintaining good health according to the American Food and Nutrition 
Board (1980) and thus should not pose any health risks to ME or non-ME 
participants. 
Time Required: 
Each participant is asked to take a single tablet on a daily basis for 
two six-week periods, with a duration of 5 months intervening between 
each six-week period. To enable us to be certain that any effects on 
mood obtained can be attributed to the mineral, participants will be 
given either the mineral tablet or a tablet with no mineral content 
during the first six-week period, followed by administration of the 
alternate tablet on the second six-week period. Participants will be 
required to spend half an hour (max one hour) answering the 
questionnaires at the beginning, midway and end of each six-week period. 
In addition, for each participant who is willing, a small sample of blood 
will be obtained by medical personnel at the beginning and end of each 
six-week period to determine the blood levels of the mineral under study. 
Name of Researcher: 
Boxd (Hank) Scott 
Name of Supervisor: 
Dr John Dalrymple-Alford 
I agree to participate in the project described above, on the 
understanding that if at any time I wish to withdraw from the 
study I may, without prejudice, do so. All personal 
information collected will be confidential as will the 






!= i" ---------------------- DATE--------
i>w are words that describe feelings and moods people have. Please read EVERY word carefully. Then fill 
(INE space under the answer which best describes how you have been feeling DURING THE PAST WEEK 
LUDING TODAY. 
'pose the word is happy. Mark the one answer which is closest to how you have been feeling DURING 
': PAST WEEK INCLUDING TODAY. 
rhe numbers refer to 
1:hese phrases: 
O = Much unlike this 
1 = Slightly unlike this 
2 = Slightly like this 
3 = Much like this 
MARKING DIREC110NS 
• USE A NO. 2 PENCIL ONLY. 
• MAKE NO STRAY MARKS. 




:;omposed .. ©000 19. Vigorous ....... ©000 37. Serene ........•. ©000 55. Ready-to-go ... ©0001 
I 
:1ngry ........ © 0 0 0 20. Dejected ....... @0 0 0 38. Bad tempered . © 0 0 0 56. Discouraged ... © 0 0 01 
I 
:;heerful. .... ©000 21. Kindly .......... @000 39. Joyful. .......... @000 57. Good-natured. ©0001 
I 
;Veak ........ ©000 22. Fatigued ....... @000 40. Self-doubting .. ©000 58. Weary· .......... ©0001 
I 
• I 
iense ........ ©000 ·23. Bold .... : .• : .... @000 41. Shaky ......•... @0@0 59. Confident ...... ©0001 
I 
:;onfused .... © 0 0 0 24. Efficient ....... @0 0 0 42. Perplexed .•.... @0 0 0 60. Businesslike ... © 0 0 01 
. I 
!.ively ........ @000 25. Peaceful. .•.... @000 43. Active ........... @000 61. Relaxed ......... ©0001 
I 
:iad .......... © 0 0 0 26. Furious ........ © 0 0 0 44. Downhearted .. © 0 0 0 62. Annoyed ....... © 0 0 01 
1 
' 
i'riendly ...... @000 27. Lighthearted .. ©000 45. Agreeable ...... ©000 63. Elated ........... ©000 
i·ired ......... ©000 28. Unsure ......... ©000 46. Sluggish ........ ©000 64. Inadequate ..... ©0001 
I 
(itrong ....... ©000 29. Jittery ........• @000 47. Forceful ......... ©000 65. Uneasy ......... ©000 
;:learheaded . © 0 0 0 30. Bewildered.... @0 0 0 48. Able to concentrate© 0 0 0 66. Dazed........... © 0 0 0 
!ntroubled .. ©000 31. Energetic ...... @000 49. Calm ............ @000 67. Full of pep ..... ©000 
! 
I 
1irouchy ..... ©000 32. Lonely ......... @000 50. Mad ............. @000 68. Gloomy ......... ©000 
I 
rayful ....... @000 33. Sympathetic .. @000 51. Jolly ............ ©000 69. Affectionate .... ©000 
rmid ........ @000 34. Exhausted .... @000 52. Uncertain ...... @000 70. Drowsy ......... ©000
1 
!11ervous ..... ©000 35: Powerful ....... ©000 53. Anxious ......... @000 71. Self-assured ... ©0001 
!I 
~ixed-u .... © 0 0 3 36. Attentive ..... . 2 0 54. Muddled ........ 
i l:i\ PSI 022 POMS Bl Copyright ~ 1980 EdlTS/ 
/t/ Educational and Industrial Testing Service, San Olego, CA 92107 ~SCANTRDN! FORM NO. T-101269-POMS IS87-C91 l·S \ J I 
,1 I don't feel I look any worse than I used to. 
I am worried that I am looking old or 
unattractive. 
I feel that there are permanent changes 
in my appearance that make me look 
unattractive. 
I believe that I look ugly. 
I can work about as well as before. 
It takes an extra effort to get started at 
doing something. 
I have to push myself very hard to do 
anything. 
I can't do any work at all. 
I can sleep as well as usual. 
I don't sleep as well as I used to. 
I wake up 1-2 hours earlier than usual 
and find it hard to get back to sleep. 
I wake up several hours earlier than I 
used to and cannot get back to sleep. 
I don't get more tired than usual. 
I get tired more easily than I used to. 
I get tired from doing almost anything. 
I am too tired to do anything. 
~fy appetite is no worse than usual. 
~fy appetite is not as good as it used to be. 
My appetite is much worse now. 




II I haven't lost much weight. if any, lately. 
I have lost more than 5 pounds. 
I have lost more than 10 pounds. 
I have lost more than 15 pounds. 
I am purposely trying to lose weight by 
eating less. Yes No 
I am no more worried about my health 
than usual. 
I am worried about physical problems 
such as aches and pains: or upset 
stomach; or constipation. 
- I am very worried about physical 
problems and it's hard to think of 
much else. 
I am so worried about my physical 
problems that I cannot think about 
anything else. 
I have not noticed any recent change 
in my interest in sex. 
I am less interested in sex than I used 
to be. 
I am much less interested in sex now. 
I have lost interest in sex completely. 
___ Subtotal Page 2 
___ Subtotal Page 1 
___ Total Score 
r PC 0528 001 6 9 10 11 12 8 C ::> E 
e,; r. Date: __________ _ 
Ii.me: ___________________ _ Marital Status: ______ Age: ____ Sex: ___ _ 
i 
:Jcupation: _________________ _ 
I 
Education: ____________________ _ 
'.Lis questionnaire consists of 21 groups of statements. After reading each group of statements carefully. 
[cle the number (0, 1, 2 or 8) next to the one statement in each group which best describes the way you 
ve been feeling the past week, including today. If several statements within a group seem to apply equally 
ill, circle each one. Be sure to read all the statements in each group before making your choice. 
I do not feel sad. 8 fl I don't feel I am any worse than 
I feel sad. anybody else. 
I am sad all the time and I can't snap out of it. I am critical of myself for my weaknesses 
or mistakes. 
I am so sad or unhappy that I can't stand it. . ·, I blame myself all the time for my faults . 
:1 I blame myself for everything bad 
I am not particularly discouraged about the that happens. 
future. 
I feel discouraged about the future. 9 I don't have any thoughts of killing myself. 
I feel I have nothing to look forward to. 
I have thoughts of killing myself. but I 
I feel that the future is hopeless and that would not carry them out. 
things cannot improve. 
I would like to kill myself. 
I do not feel like a failure. 
:1 I would kill myself if I had the chance. 
I feel I have failed more than the 
10 average person. fl I don't cry any more than usual. 
As I look back on my life, all I can see is I cry more now than I used to. 
a lot of failures. I cry all the time now. 
I feel I am a complete failure as a person. :\ I used to be able to cry, but now I can't cry 
even though I want to. 
I get as much satisfaction out of things as I 
used to. 11 fl I am no more irritated now than I ever am. 
I don't enjoy things the way I used to. I get annc,yed or irritated more easily than 
I don't get real satisfaction out of anything I used to. 
anymore. - I feel irritated all the time now. 
I am dissatisfied or bored with everything. ;J I don't get irritated at all by the things :hat 
used to irritate me. 
I don·t feel particularly guilty. 
I feel guilty a good part of the time. 12 fl I have not lost interest in other people. 
I feel quite guilty most of the time. I am less interested in other people than 
I feel guilty all of the time. I used to be. 
- I have lost most of my interest in 
I don't feel I am being punished. other people. 
I feel I may be punished. 
:I I have lost all of my interest in other people. 
I expect to be punished. 
13 I feel I am being punished. () I make decisions about as well as 
I ever could. 
I don't feel disappointed in myself. 
I put off making decisions more than 
I used to. 
I am disappointed in myself. - I have greater difficulty in making 
I am disgusted with myself. decisions than before. 
I hate myself. :J I can't make decisions at all anymore. 
___ Subtotal Page 1 CONTINUED ON BACK 
\Tl, fl II' l'~Y( :1-J( )i.l l( ;1c ',\I. ( :( )Rl'llRATll )N 
r- I 1.-\IU :t ll lfff BRACE ll lV-\Nl 'VIOi. INC. 
Copyright · 1978 by Aaron T. Beck. All rights reserved. Printed in the U.S.A. 
NOTICE: It rs against the law to photocopy or otherwise reproduce 
this questionnaire without the publisher's written permission. 9·018359 
' 
INFORMATION SHEET 
You are being asked to take part as a volunteer in the following 
research 
This study is being conducted so that an understanding of the stress, 
feeling of tiredness and fatigue and associated moods of depression 
and anxiety can be evaluated in relation to a specific mineral 
supplementation in the daily diet of Myalgic Encephalomyelitis subjects 
It is also carried out as part fulfilment of a Thesis requirement for 
the Master of Science degree in Psychology at the University of 
Canterbury. 
WHAT WILL YOU BE EXPECTED TO DO 
Your stress and mood states will be evaluated both before, during and 
after each six.week trial period. This evaluation will require your 
filling out a couple of questionnaires. 
Blood samples will also. be collected from willing subjects so that a 
check on mineral blood levels can be performed. 
h 
The mineral supplementation period will involve your taking cf a single 
pill each day for six weeks. After the first six weeks trial you will 
be ona five month wash-out period when you •ill be frae from any 
mineral pills. 
The whole procedure is then repeated for another six weeks. 
HOW MUCH TIME WILL IT TAKE? 
About eight months in total from start to finish. 
WHAT ARE THE RISKS 
There are no anticipated risks to subjects in this study. 
·,vr:L THE INFOfiMATICN BE CONFIDENTIAL? 
·:i::.e identity of each subject and any information they supply for the 
study will remain confidential at all times. 
' 
2 
CAN YOU WITHDRAW AT ANY TiivlE? 
Each subject is free to withdr.aw anytime from any part or all 
of the research programme without prejudice to any present or 
future treatment. 
WHO SHOULD YCU DISCUSS THIS WITH? 
You should feel free to discuss this pro~ramme with other members 
of your ME support group and a close relative or friend. You 
should also contact your own physician should you feel the need 
for medical consultation. In this respect I will be available 
to discuss the programme with other support services you make 
contact with. 
Dr John Dalrymple-Alford (Department Psychology, University of 
Canterbury) will also be available for consultations in respect 
to this study. 
DEBRIEFING PROCEDURE 
Each subject will be notified of the results of this study. They 
will be told of the actual mineral they too~ and '.iVhen they were 
on it during the study. Any relevant results of blood tests will 
also be made known where applicable. The overall result of the 
programme will be explained to all subjects ~hen the results have 
been fully analysed. 
DEPARTMENT OF PSYCHOLOGY, UNIVERSITY OF CANTERBURY 
_ CONFIDENTIAL SUBJECT QUESTIONNAIRE(EX) 
NAME: ________________ MR/MRS/MISS 
(Surname) -· • (First Name) 
DATE OF BIRTH __________ PHONE ___ "_---__ _ 
TOWN & COUNTRY OF BIRTH: ____ _ 
RACE OR ETHNIC ORIGIN: AGE: --------------· 
.............................................. **************** 
--- --= --- ·-
1. How long is it since you were ·first diagnosed as having ME/CFS? ____ _ 
2. Name of doctor who made the diagnosis? ___________ _ 
3. Where have you lived most of your life? ___________ _ 
4. In the last five years? ________________ _ 
5. Brief summary of past illnesses not related to ME ________ _ 
6. Present level of ME condition (High/Medium/Low/Non-existent)? ____ _ 
7. How often do these bouts recur? --------------
8. Any major operations? _______________ _ 
9. Number of pregnancies? _ Number of children? _ Age of eldest? _ 
10. Does any other relative have ME or have had it? YES/NO (Give relationship, 
e.g. sister, uncle, etc) ______ _ 
11. Level of Active Participation in cultural and Sporting Interests: 
(a) List sports involved in at present: ___________ _ 
(b) List past involvement in sports:------,--------
-- .(c) List cultural. activities. engaged in at present, e.g. tramping, Bridge, etc. 
' (d) List past cultural activities no longer involved in: _______ _ 
{f'l!EASE TURN OVER THE PAGE) 
12. Sleep Patterns: 
Give any changes in s!aap hab:ts sinc:3 contacting ME: ________ _ 
13. Is there any part of the day you feel more active? _________ _ 
14. Do you feel better any particular months of the year? ________ _ 
15. Eating Habits: (Please be "precise" in your answers to this question) 
(a) List dislikes: -------------------
(b) List major source of the following - indicate how often they are consumed 
{per week, month, etc.) 
(i) Proteins: (cheese, fish, eggs, meat (type)) 
(ii) Carbohydrates: (sugars, starches) __________ _ 
(iii) Fluids: __________________ _ 
(iv) Fruits & Cereals: _______________ _ 
(~!EXT ?AG!E PLEASE) 
THE FOLLOWING IS AN OPTIONAL SECTION WHICH WOULD BE HELPFUL TO 
OUR STUDY DESIGN: 
A. Years of secondary schooling compfeted: __ _ 
B. Years of tertiary (technicaVuniversity) schooling completed: __ _ 
C. What is your present occupation? ______________ _ 
D. What other occupations have you held? ____________ _ 
E. Have you ever lost a job because of ME/CFS? __ Explain: ______ _ 
F. What in your view may have started your ME/CFS condition? ______ _ 
G. Are your family and close friends sympathetic and supportive of your situation since 
your ME/CFS diagnosis? 
H. HEIGHT _____ _ WEIGHT ______ _ 
Date: ----------
Thank you for completing this questionnaire and your support in this work. 
B,H SCOTT 
Please return to: 13 Kingslea St. Oamaru 
(c) List any mineral and vitamin s~pplement (Please give brand name(s) and no. 
of taken daily): 
(i) Currently Using: _______________ _ 
(ii) Were Using: ________________ _ 
(iii) Special Diets: (Indicate any professional advice) ______ _ 
16. Allergies: ___________________ _ 
17. Any Other Significant Changes to Your Health Since Contacting ME? ____ _ 
18. Name of Present Doctor: ----------------
Address/Surgery:------------------
Phone: --------
YOUR ADDRESS _________________ _ 
(Pl!EASIE TUPd~ OVIER THIE PAGIE) 
